Healthequity, INC Form 4 insider transactions

HealthEquity's EVP & CFO, James M. Lucania, reported a sale of 4,393 shares of common stock on April 6, 2026.

HealthEquity, Inc. President and CEO Scott Cutler reported a transaction involving the acquisition of common stock.

HealthEquity Inc. EVP, General Counsel Delano Ladd reported a sale of 7,726 shares of common stock on March 31, 2026.

Stephen Neeleman, Founder and Vice Chairman of HealthEquity, Inc., reported transactions involving common stock and stock options.

HealthEquity Inc. EVP, Chief Technology Officer Elimelech Rosner reported a sale of 18,010 common shares on March 31, 2026.

HealthEquity's EVP and General Counsel, Delano Ladd, increased direct beneficial ownership through the vesting and grant of restricted stock units.

HealthEquity's Chief Customer Officer, Michael Gathright, was granted 15,157 restricted stock units, aligning his interests with shareholders.

Stephen Neeleman, Founder and Vice Chairman of HealthEquity, reported the acquisition of common stock through restricted stock units and disclosed existing stock options.

HealthEquity's EVP, Chief Commercial Officer Michael Fiore was granted 17,582 restricted stock units, aligning executive incentives with long-term company performance.

HealthEquity's EVP and Chief Technology Officer, Elimelech Rosner, increased his direct beneficial ownership of common stock through the vesting and grant of restricted stock units.

HealthEquity's EVP & CFO, James M. Lucania, was granted 27,283 restricted stock units, vesting over several years.

HealthEquity, Inc. President and CEO Scott Cutler reported the acquisition of 72,754 restricted stock units, increasing his beneficial ownership.

HealthEquity Director Stuart B. Parker reported the vesting of 1,263 restricted stock units, increasing his direct beneficial ownership.

HealthEquity Director Rajesh Natarajan reported the acquisition of 976 common shares through the vesting of restricted stock units.

HealthEquity's President and CEO, Scott Cutler, disposed of 12,496 shares of common stock to cover tax withholding obligations.

HealthEquity's EVP, Chief Commercial Officer, Michael Henry Fiore, disposed of 1,744 shares of common stock to cover tax withholding obligations at a price of $95.2361 per share.

HealthEquity's EVP & CFO, James M. Lucania, disposed of 2,470 shares of common stock at a weighted average price of $95.236 in a pre-planned transaction.

HealthEquity's EVP and Chief Technology Officer, Elimelech Rosner, disposed of 2,074 shares of common stock to cover tax withholding obligations.

HealthEquity's Founder and Vice Chairman, Stephen Neeleman, reported the sale of 791 common shares on January 9, 2026, at a weighted average price of $95.2367.

HealthEquity's EVP and General Counsel, Delano Ladd, reported a planned disposition of 739 common shares for tax liabilities under a 10b5-1 plan.

HealthEquity's Founder and Vice Chairman, Stephen Neeleman, reported a gift of 140,000 common shares to his spouse for estate planning purposes.

HEALTHEQUITY's EVP and General Counsel, Delano Ladd, sold 1,500 shares of common stock for $94.72 per share, reducing his direct beneficial ownership to 73,979 shares, as part of a pre-arranged 10b5-1 trading plan.

HealthEquity's EVP and Chief Technology Officer, Elimelech Rosner, sold 10,959 shares of common stock for approximately $1.04 million under a pre-arranged trading plan.

Stephen Neeleman, Founder and Vice Chairman of HealthEquity, reported a gift of 500 shares of common stock and updated his beneficial ownership.

HealthEquity Director Gayle Furgurson Wellborn exercised stock options and subsequently sold a portion of her common stock holdings.

HealthEquity's EVP and General Counsel, Delano Ladd, sold 1,500 shares of common stock for $104.56 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

Delano Ladd, EVP and General Counsel of HealthEquity, Inc., executed a pre-planned sale of 1,500 shares of common stock at $92.07 per share.

HealthEquity's EVP, General Counsel, Delano Ladd, disposed of 977 common shares to cover tax withholding obligations at a price of $88.5674 per share.

HealthEquity's EVP & CFO, James M. Lucania, reported a planned disposition of 2,393 shares of common stock on October 6, 2025, at $88.5674 per share to cover tax liabilities.

Stephen Neeleman, a Director and Founder of HealthEquity, disposed of 1,058 common shares to cover tax liabilities.